84343 20210507081948.0 doi 10.1177/0269881119856546 sideral 113129 ART-2019-113129 eng Latorre, Eva Universidad de Zaragoza (orcid)0000-0002-5797-3909 Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders 2019 Access copy available to the general public Unrestricted Background: The serotonergic system is a key component of physiological brain function and is essential for proper neurological activity. Numerous neuropsychiatric disorders are associated with deregulation of the serotonergic system. Accordingly, many pharmacological treatments are focused on modulation of this system. While providing a promising line of therapeutic moderation, these approaches may be complicated due to the presence of alternative splicing events for key genes in this pathway. Alternative splicing is a co-transcriptional process by which different mRNA transcripts can be produced from the same gene. These different isoforms may have diverse activities and functions, and their relative balance is often critical for the maintenance of homeostasis. Alternative splicing greatly increases the production of proteins, augmenting cell plasticity, and provides an important control point for regulation of gene expression. Aim: The objective of this narrative review is to discuss the potential impact of alternative splicing of different components of the serotonergic system and speculate on their involvement in several neuropsychiatric disorders. Conclusions: The specific role of each isoform in disease and their relative activities in the signalling pathways involved are yet to be determined. We need to gain a better understanding of the basis of alternative isoforms of the serotonergic system in order to fully understand their impact and be able to develop new effective pharmacological isoform-specific targets. info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.121 2019 CLINICAL NEUROLOGY 75 / 204 = 0.368 2019 Q2 T2 PSYCHIATRY 57 / 154 = 0.37 2019 Q2 T2 PHARMACOLOGY & PHARMACY 103 / 270 = 0.381 2019 Q2 T2 NEUROSCIENCES 126 / 271 = 0.465 2019 Q2 T2 1.342 2019 Medicine (miscellaneous) 2019 Q1 Psychiatry and Mental Health 2019 Q1 Pharmacology (medical) 2019 Q1 Pharmacology 2019 Q1 info:eu-repo/semantics/review info:eu-repo/semantics/acceptedVersion Mesonero, Jose Emilio Universidad de Zaragoza (orcid)0000-0003-4758-3998 Harries, Lorna W. 1005 410 Universidad de Zaragoza Dpto. Farmacología y Fisiolog. Área Fisiología 1002 050 Universidad de Zaragoza Dpto. Bioq.Biolog.Mol. Celular Área Biología Celular 33, 11 (2019), 1352-1363 J. psychopharmacol. JOURNAL OF PSYCHOPHARMACOLOGY 0269-8811 348572 http://zaguan.unizar.es/record/84343/files/texto_completo.pdf Postprint 73113 http://zaguan.unizar.es/record/84343/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:84343 articulos driver 2021-05-07-08:11:26 ARTICLE